TipRanks on MSN

Milestone’s PSVT nasal spray MAA accepted by EMA

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...
TipRanks on MSN

Milestone announces acceptance of MAA by EMA for etripamil nasal spray

Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, ...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

Fund manager, 47, dies of sudden cardiac arrest while on holiday: How young Indians can get a simple test and prevent this silent heart risk

Focussing only on heart attacks may be incomplete. Listen to your heartbeat closely to prevent sudden cardiac arrest, says ...
IEEE

Comparison of Performance on MRT, MCT, PSVT and HSVT Spatial Ability Tests between Paper and Desktop Display

Abstract: This study investigates the spatial ability skills of engineering students using four different tests: the Mental Rotation Test, Mental Cutting Test, Purdue Spatial Visualization Test, and ...
Business Wire

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
MedPage Today

Etripamil Gets FDA Approval for At-Home Tachycardia Conversion

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
Investing

Aptar’s nasal spray system to deliver newly approved PSVT treatment

CRYSTAL LAKE, Ill. - Aptar Group, Inc. (NYSE:ATR) announced that its Bidose Liquid Nasal Spray System will be used to deliver CARDAMYST (etripamil), a treatment recently approved by the U.S. Food and ...